Sino Biopharmaceutical Ltd

1177.HK · Health Technology · Pharmaceuticals: Major · HK

23,302 employees · sinobiopharm.com

About

Sino Biopharmaceutical Ltd is a leading biopharmaceutical company in China that focuses on research, development, production, and distribution of medications. The company is headquartered in Hong Kong and is listed on the Hong Kong Stock Exchange. The company was founded in 2000 by Dr. Tse Ping, an experienced entrepreneur in the chemical industry. The goal was to develop innovative medications that could improve people's health and lives. Since then, Sino Biopharmaceutical has become a major player in the pharmaceutical industry. Sino Biopharmaceutical's business model is based on three pillars: generics, innovative medications, and contract manufacturing. The company specializes in the development and production of generics to make affordable, high-quality medications accessible to the masses. At the same time, the company also invests in research and development of innovative medications for rare and serious diseases. Additionally, Sino Biopharmaceutical also offers contract manufacturing services to other companies. Sino Biopharmaceutical operates in four divisions: pharmaceutical manufacturing, research and development of biopharmaceutical medications, contract manufacturing, and sales and marketing activities. Pharmaceutical manufacturing includes the production of generics as well as the manufacturing of medications for specific indications. Research and development of biopharmaceutical medications focuses on the development of therapies for severe and rare diseases. Contract manufacturing involves the manufacturing process from raw material sourcing to packaging medications for other companies. Sales and marketing activities involve positioning and promoting Sino Biopharmaceutical's products in the market. Some of Sino Biopharmaceutical's well-known products include Hengrui Medicine, an anticancer medication used to treat cancer; Yigu, a medication for liver diseases; and Tongbi, a medication for osteoporosis. Sino Biopharmaceutical has a strong presence in the Chinese market, as well as the international market. The company exports its products to over 60 countries worldwide. Sino Biopharmaceutical has also become a key partner for international companies and regularly collaborates with other pharmaceutical corporations to expand their expertise in product development and manufacturing. In summary, Sino Biopharmaceutical Ltd is a major player in the pharmaceutical industry that specializes in the development and production of generics and innovative medications. There is also a focus on contract manufacturing of medications for other companies. The company has a strong presence in the Chinese market and exports its products to over 60 countries.

Annual results

Reported figures, CNY · revenue up 29.3% in 2025

YearRevenueNet incomeNet marginFree cash flow
202531.8B2.3B7.4%—
202424.6B3.0B12.1%—
202326.2B2.3B8.9%—
202222.2B2.2B9.8%—
202126.9B14.6B54.4%—

Dividends per share

2026 0.05 CNY2025 0.09 CNY2024 0.06 CNY2023 0.08 CNY2022 0.10 CNY

1177.HK in MarketPulse

The live chart with RSI and moving averages, the price, news, signals and price alerts for Sino Biopharmaceutical Ltd are inside MarketPulse — currently in private beta.

Company data by Eulerpool. Logos provided by Elbstream. Reported figures, not investment advice.

Sino Biopharmaceutical Ltd (1177.HK) — company profile and financials · MarketPulse